Mendlewicz J
Free University of Brussels, Department of Psychiatry, Belgium.
Int Clin Psychopharmacol. 1999 May;14 Suppl 1:S17-20. doi: 10.1097/00004850-199905001-00004.
The introduction of selective serotonin reuptake inhibitors (SSRIs) has helped clarify our understanding of the actions of serotonin in depression. The serotonergic network of the central and peripheral nervous systems comprises many different pathways and at least 14 distinct serotonin receptors. By using our knowledge of neuroanatomy and the pharmacology of SSRIs, it is possible to predict many of the therapeutic and non-therapeutic effects of modulating serotonin levels. The efficacy of SSRIs in mild to moderate depression is well established but their efficacy in severe depression varies, compared with tricyclic antidepressants. The SSRIs also have predictable effects in a range of other affective disorders including obsessive-compulsive disorder, anxiety and bulimia, the efficacy varying between the different SSRIs. The adverse event profile is different from that of the tricyclic antidepressants and again is predictable through an understanding of the different serotonergic pathways.
选择性5-羟色胺再摄取抑制剂（SSRIs）的引入有助于我们更清楚地了解血清素在抑郁症中的作用。中枢神经系统和外周神经系统的血清素能网络由许多不同的途径和至少14种不同的血清素受体组成。通过运用我们对神经解剖学和SSRIs药理学的了解，可以预测调节血清素水平的许多治疗和非治疗效果。SSRIs在轻至中度抑郁症中的疗效已得到充分证实，但与三环类抗抑郁药相比，它们在重度抑郁症中的疗效有所不同。SSRIs在一系列其他情感障碍中也有可预测的效果，包括强迫症、焦虑症和贪食症，不同SSRIs的疗效各不相同。其不良事件谱与三环类抗抑郁药不同，同样通过了解不同的血清素能途径也可预测。
